GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

GNI Group announced the acquisition of Ayumi Pharmaceutical Holdings for approximately ¥44.8 billion, making it a wholly owned subsidiary. The transaction establishes a large-scale pharmaceutical platform in Japan with leading positions in pain management and rheumatology, expected to increase combined fiscal 2026 revenue to approximately ¥65.2 billion. The acquisition strengthens GNI Group's commercial capabilities and geographic diversification across Japan, China, and the United States.